Drug Profile

ALTY 0501

Alternative Names: ALTY-0501; Doxycycline topical - Alacrity Biosciences

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Miami
Developer Alacrity Biosciences
Class Antibacterials; Antimalarials; Antineoplastics; Skin disorder therapies; Small molecules; Tetracyclines
Mechanism of Action Metalloprotease inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Dry eyes

Most Recent Events

17 Apr 2012 Discontinued - Phase-II for Dry eyes in USA (Topical)
12 Oct 2007 Final results from a phase II clinical trial in Dry eyes added to the Eye Disorders therapeutic trials section
31 Aug 2007 Alacrity Biosciences completes a phase II trial in Dry eyes in the US

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com